Press Releases

 
Press Releases
  Date Title and Summary View
Aug 15, 2017
First Amicus Medicine and First Oral Precision Medicine for Fabry Disease in Australia Broad Label for Fabry Patients with an Amenable Genetic Mutation CRANBURY, N.J., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) announced that the Australian Therapeutic Goods Administration (TGA) has approved the oral precision medi...
PDF
Aug 7, 2017
179 Fabry Disease Patients on Reimbursed Galafold (migalastat) as of July 31 - On Target to Reach 300 Patients by Year-End 2017 Migalastat NDA Submission Targeted for 4Q17 Phase 3 EB Topline Data and Complete Phase 1/2 Pompe Data on Track for Late 3Q17 CRANBURY, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a g...
PDF
Jul 25, 2017
CRANBURY, N.J., July 25, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on August 7, 2017 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2017. The call will be hosted by John F. Crowley, Chairman and Chief Executive Officer. He will be jo...
PDF
Jul 18, 2017
CRANBURY, N.J., July 18, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced the closing of its previously announced offering of common stock. Prior to the closing, the underwriters exercised in full their option to purchase an addit...
PDF
Jul 12, 2017
CRANBURY, N.J., July 12, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced the pricing of an underwritten offering of 18,367,347 shares of its common stock at $12.25 per share. The gross proceeds from the offering to Amicus are exp...
PDF
Jul 12, 2017
CRANBURY, N.J., July 12, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced it has commenced a $225 million underwritten public offering of its common stock. J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC are acting as joint bo...
PDF
Jul 11, 2017
Data Deemed Sufficient to Support NDA Submission NDA Submission Targeted for 4Q17 Conference Call Today at 8:30am ET CRANBURY, N.J., July 11, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) plans to submit a new drug application (NDA) to the U.S. FDA for the oral precision medicine migalastat for Fabry disease in the four...
PDF
Jun 28, 2017
CRANBURY, N.J., June 28, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, has submitted a Japanese new drug application (J-NDA) to the Pharmaceuticals and Medical Devices Agency (PMDA) to request marketing authorization for migalastat, an oral precision medici...
PDF
Jun 7, 2017
CRANBURY, N.J., June 07, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (Nasdaq:FOLD) announced today that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the upcoming Goldman Sachs 38th Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Thursday, June 15, 201...
PDF
May 31, 2017
Designation Covers Broad Treatment of Epidermolysis Bullosa (EB) Top-Line Phase 3 Data on Track for 3Q17 CRANBURY, N.J., May 31, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (Nasdaq:FOLD), has received Rare Pediatric Disease designation1 from the U.S. Food and Drug Administration (FDA) for the novel topical medicine SD-101 for the tre...
PDF
Page:
1
... NextLast